Grünenthal to distribute, promote, and sell MSD's Women's Health products in several countries in Latin America

Aachen (ots) - Grünenthal announced today that it has entered into
a distribution agreement with MSD (tradename of Merck & Co., Inc.,
Kenilworth, N.J., USA) for distributing, promoting and selling MSD's
Women's Health products in Brazil, Central America, Colombia, Mexico
and Peru. The portfolio comprises several Women's Health products,
including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will
continue to commercialize Nexplanon®/Implanon NXT® throughout that
region.

"This agreement represents a major contribution to Grünenthal's
overall growth. Women's Health is one of our strategic priorities for
Latin America. Therefore, we are delighted that MSD has chosen us to
distribute, promote, and sell Women's Health products that are a
perfect complement to our existing offerings in this region. The
addition of these products to our portfolio will enable us to
establish an even stronger footprint in key markets like Brazil and
Mexico and become the 2nd largest Women's Health company in Latin
America," Gabriel Baertschi, Chief Executive Officer Grünenthal,
explains. "We are now at the forefront of supporting women's health
in the region," he stated.

Further terms of the agreement were not disclosed. Grünenthal will
take over the distribution, promotion and sales of a product
portfolio with attractive growth prospects across Latin America. The
agreement propels Grünenthal to become the 2nd largest Women's Health
company in this region with revenues above EUR 110 million.

Women's Health is one of Grünenthal's strategic priorities in
Latin America. In January 2017, Grünenthal introduced its Chilean
hormone plant, which is the company's center of excellence for
hormone production. It is the most modern facility of its kind in
Latin America and improves access to high quality health products for
women across the region.

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a EUR 2
billion company. We are a fully integrated research & development
company with a long track record of bringing innovative pain
treatments and state-of-the-art technologies to patients. By
sustainably investing in our R&D above the industrial average, we are
strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in 32 countries with affiliates in
Europe, Latin America and the US. Our products are sold in more than
155 countries and approx. 5,500 employees are working for the
Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of
approx. EUR 1.4 bn.

More information: www.grunenthal.com

Follow us on LinkedIn: "GrunenthalGroup"

###

Contact:
Stepan Kracala, Global Head Corporate Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com

Original-Content von: Grünenthal Group, übermittelt durch news aktuell